Univest Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Univest Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.15M	Buy	7,063 +966	+16%	+$450K	0.18%	89
2025 Q4	$2.76M	Sell	6,097 -1,267	-17%	-$546K	0.15%	106
2025 Q3	$2.88M	Buy	7,364 +1,388	+23%	+$580K	0.16%	98
2025 Q2	$2.66M	Buy	5,976 +2,086	+54%	+$961K	0.16%	100
2025 Q1	$1.89M	Buy	+3,890	New	+$1.81M	0.12%	121

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Univest Financial's VRTX Position: Q1 2026 in Review

Univest Financial increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, buying an estimated $450K and bringing the position to 7,063 shares worth $3.15M. The position accounts for 0.18% of the portfolio, ranked #89.

Univest Financial first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Univest Financial held 7,063 shares of Vertex Pharmaceuticals worth $3.15M as of Q1 2026.
Univest Financial bought 966 Vertex Pharmaceuticals shares in Q1 2026, an estimated $450K.
Vertex Pharmaceuticals made up 0.18% of Univest Financial's portfolio in Q1 2026, its #89 holding.
Univest Financial first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Univest Financial's 13F filing for Q1 2026, filed 1 May 2026.